Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
fnarena9h
ResMed: Another Positive Quarterly Surprise?
UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...
Revere Journal15h
GLP-1 Weight-loss Drugs Should be made Affordable for All Americans
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
New study reveals what Americans perceive as ideal weight
Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...
Resbiotic Expands Global Footprint with Strategic Distribution Agreement in Mexico
Resbiotic Nutrition Inc. ("resbiotic" or "res"), a leading provider of physician-formulated and science-backed dietary supplements, has announced a strategic distribution agreement with Grupo Columbia ...